Gerrit Los, PhD
About Gerrit Los, PhD
Gerrit Los is the Chief Scientific Officer for San Diego Operations, with a distinguished career in oncology and pharmacology research, including significant contributions to the development of targeted cancer therapeutics.
Chief Scientific Officer - San Diego Operations
Gerrit Los holds the position of Chief Scientific Officer for the San Diego operations. In this role, he oversees scientific initiatives and leads research and development efforts aimed at advancing cancer therapeutics. His extensive experience in the field of oncology pharmacology informs his strategic direction of various projects. His leadership is crucial for driving innovation and ensuring the scientific rigor of the company's research endeavors.
Education and Expertise
Gerrit Los earned his PhD in Oncology/Pharmacology from the Free University in Amsterdam. His academic background provided a strong foundation for his subsequent research and professional roles. His expertise is further solidified by a post-doctoral fellowship at the Netherlands Cancer Institute, funded by the Dutch Cancer Society. Los's education and specialized knowledge in cancer biology and pharmacology have enabled him to contribute significantly to the field.
Background in Oncology Research at Pfizer
From 2002 to 2012, Gerrit Los served as the Director of Cancer Biology and later as the Senior Director of the Oncology Research Unit at Pfizer. During his tenure, he directed teams focused on the development of targeted cancer therapeutics, including pivotal drugs such as crizotinib and palbociclib. His role involved overseeing significant aspects of cancer drug research and development, contributing to the advancement of these treatments from the laboratory to clinical applications.
Leadership at AnaptysBio and Five Prime Therapeutics
Gerrit Los took on the role of Vice President of Pharmacology at AnaptysBio in San Diego, where he directed the preclinical development of lead compounds aimed at Phase 1 clinical trials. His leadership continued at Five Prime Therapeutics in South San Francisco from 2012 to 2015, where he was instrumental in developing several oncology assets. His strategic vision and direction played a crucial role in the progression of promising cancer therapies.
Academic Contributions and Publications
Gerrit Los has an impressive academic and research portfolio, having published more than 100 peer-reviewed papers and contributing to 8 book chapters. Additionally, he has over 250 published abstracts. His role as an Adjunct Professor at the University of California San Diego allowed him to direct a pharmacogenomics/molecular pharmacology program, furthering the scientific community's understanding of these fields. Los also reviews multiple high-impact cancer journals, ensuring the quality and integrity of published research.